Author/Editor		Slaviček, J; Puretić, Z; Glavaš-Boras, S; Šmalcelj, R; Bubić-Filipi, Lj; Barišić, I
Title		Low-dose intradermal hepatitis B vaccination in chronic hemodialysis patients
Type		članek
Source		In: Lindič J, Kaplan-Pavlovčič S, editors. Zbornik prispevkov 1. slovenski nefrološki kongres z mednarodno udeležbo; 1996 okt 23-26; Portorož. Ljubljana: Klinični center, Nefrološka klinika,
Publication year		2000
Volume		str. 181-3
Language		eng
Abstract		The purpose of the work was to investigate whether in patients (pts) on long-term haemodialysis (HD) non-responders (NR) to classically applied IM vaccination against hepatitis B seroconversion can be obtained by applying the vaccine intradermally, and whether in low responders (LR) antibody titer can in this way be increased. Engerix B vaccine was applied in 20 pts on chronic HD - 10 m, 10 f, age span 19-74 yrs. The following protocol was obeyed: 5.0 microg of the vaccine every 14 days, until the protection titer was achieved; then once monthly. Seroconversion was attained in 13/14 pts (93%), with anti-HBs titer from 15 to >1.000 IU/L (x 223.4 IU/L). The 4 LR were also vaccinated. Two of them developed the titer over 1.000 IU/L, one 286 IU/L, and 1 remained a LR. Adverse reactions were: a transitory rash and pruritus with local mild induration in 4 pts. The study proves that by applying intradermal vaccination, seroconversion can be attained in almost a 100% of pts using, as a rule, a lower dose of the vaccine. However, the titer is lower and the effect shorter than when the vaccine is applied IM, so that more frequent booster doses are necessary.
Descriptors		KIDNEY FAILURE, CHRONIC HEPATITIS B VACCINES HEPATITIS B SURFACE ANTIGENS INJECTIONS, INTRADERMAL